Unknown

Dataset Information

0

Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".

ABSTRACT: Significant advances were made in antibiotic development during the past 5 years. Novel agents were added to the arsenal that target critical priority pathogens, including multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacterales. Of these, 4 novel β-lactam-β-lactamase inhibitor combinations (ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-cilastatin-relebactam) reached clinical approval in the United States. With these additions comes a significant responsibility to reduce the possibility of emergence of resistance. Reports in the rise of resistance toward ceftolozane-tazobactam and ceftazidime-avibactam are alarming. Clinicians and scientists must make every attempt to reverse or halt these setbacks.

SUBMITTER: Papp-Wallace KM 

PROVIDER: S-EPMC7609624 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis.
| S-EPMC8139903 | biostudies-literature
Unknown ?-lactam/?-lactamase inhibitor combinations: an update.
| S-EPMC6151480 | biostudies-literature
Genomics Mutational resistance to novel cephalosporin-β-lactamase inhibitor combinations
| PRJEB44132 | ENA
Unknown In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing Klebsiella pneumoniae: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of β-Lactam Plus Novel β-Lactamase Inhibitor or β-Lactam Enhancer Combinations.
| S-EPMC8614831 | biostudies-literature
Unknown Escape mutations circumvent a tradeoff between resistance to a beta-lactam and resistance to a beta-lactamase inhibitor.
| S-EPMC7181632 | biostudies-literature
Unknown Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis ?-Lactamase BlaC lead to clavulanate resistance?: a biochemical rationale for the use of ?-lactam-?-lactamase inhibitor combinations.
| S-EPMC3837893 | biostudies-literature
Unknown Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
| S-EPMC5896976 | biostudies-other
Unknown Synergistic, collaterally sensitive β-lactam combinations suppress resistance in MRSA.
| S-EPMC4618095 | biostudies-literature
Unknown Unorthodox Parenteral ?-Lactam and ?-Lactamase Inhibitor Combinations: Flouting Antimicrobial Stewardship and Compromising Patient Care.
| S-EPMC7179625 | biostudies-literature
Unknown Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux Pump.
| S-EPMC8284450 | biostudies-literature